No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19

BACKGROUND: Dipeptidyl peptidase-4 (DPP4) is commonly targeted to achieve glycemic control and has potent anti-inflammatory and immunoregulatory effects. Recent structural analyses indicated a potential tight interaction between DPP4 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiang-Hua, Wu, Bin, Wang, Wen-Xin, Lei, Fang, Cheng, Xu, Qin, Juan-Juan, Cai, Jing-Jing, Zhang, Xiao-Jing, Zhou, Feng, Liu, Ye-Mao, Li, Hao-Miao, Zhu, Li-Hua, She, Zhi-Gang, Zhang, Xin, Yang, Juan, Li, Hong-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716296/
https://www.ncbi.nlm.nih.gov/pubmed/33344548
http://dx.doi.org/10.12998/wjcc.v8.i22.5576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716296/
https://www.ncbi.nlm.nih.gov/pubmed/33344548
http://dx.doi.org/10.12998/wjcc.v8.i22.5576

Ejemplares similares